Hence, AIM2-deficient DC vaccination not only enhances immune responses to the tumor by activating STING but also suppresses IL-1β and IL-18 production, resulting in synergistic therapeutic responses (Figure 3). This evidence concerns the gene AIM2 and neoplasm.